AR and cancer: A plausible explanation emerged when a chimeric mouse model of mCRPC exhibited compromised T-cell activation due to inhibition of Src family kinases69, revealing that CRPC-effective inhibitors are likely to be those that not only silence AR/AR-V768, but also do not compromise ability of T lymphocytes to attack cancer cells.